Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
暂无分享,去创建一个
S. Steinberg | H. Parnes | J. Trepel | J. Wright | W. Figg | Scot A. Niglio | K. Chan | S. Pal | A. Apolo | R. Nadal | P. Lara | Min-Jung Lee | Sunmin Lee | Liang Cao | D. Bottaro | R. Costello | A. Mortazavi | A. Toubaji | E. Sharon | H. Chalfin | H. Streicher | B. Saraiya | S. Gurram | M. Merino | V. Valera | D. Girardi | Yunkai Yu | L. Cordes | B. Redd | Y. Ning | L. Ley | Jacqueline Cadena | Carlos Diaz | H. Bagheri | Olena Sierra Ortiz
[1] M. Milowsky,et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). , 2021 .
[2] T. Powles,et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.
[3] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[4] N. Karin. The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative , 2020, Frontiers in Immunology.
[5] C. Drake,et al. Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805) , 2020, The Prostate.
[6] Craig B. Davis,et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. , 2020, The New England journal of medicine.
[7] S. Steinberg,et al. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Christensen,et al. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC) , 2020 .
[9] S. Steinberg,et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. , 2020, The Lancet. Oncology.
[10] M. Galsky,et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[11] P. Hegde,et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.
[12] Hongyu Zhao,et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.
[13] Ash A. Alizadeh,et al. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC , 2020, Clinical Cancer Research.
[14] S. Pal,et al. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence , 2019, Molecular Cancer Therapeutics.
[15] M. Knopp,et al. 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[16] J. Schlom,et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors , 2019, Journal of Immunotherapy for Cancer.
[17] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.
[18] V. Servois,et al. Novel patterns of response under immunotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] J. Hajdenberg,et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. , 2019, Journal of Clinical Oncology.
[20] Jean-David Fumet,et al. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients , 2019, Oncoimmunology.
[21] P. Meltzer,et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations , 2018, Journal of Immunotherapy for Cancer.
[22] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[23] G. Sica,et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.
[24] E. Plimack,et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.
[25] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[26] S. Steinberg,et al. A Phase II Clinical Trial of TRC105 (Anti‐Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma , 2017, Clinical genitourinary cancer.
[27] Jens Eickhoff,et al. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study , 2016, The Journal of Nuclear Medicine.
[28] Peter J. Murray,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.
[29] M. Schell,et al. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab , 2016, Cancer Immunology Research.
[30] F. Hodi,et al. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data , 2015, Front. Oncol..
[31] C. Bai,et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell‐derived hepatocyte growth factor through ERK1/2 , 2014, Journal of leukocyte biology.
[32] S. Steinberg,et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. , 2014 .
[33] S. Culine,et al. [Management of metastatic bladder cancer]. , 2014, La Revue du praticien.
[34] E. Tartour,et al. Modulation of Immunity by Antiangiogenic Molecules in Cancer , 2012, Clinical & developmental immunology.
[35] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[36] Pedro Romero,et al. Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes1 , 2007, The Journal of Immunology.